Natriuretic peptides in the pathogenesis and diagnosis of chronic heart failure by Noroc, Victoria
The 8th International Medical Congress for Students and Young Doctors 
 ____________________________________________________________________________________ 
270 
 
consequences. Thus, conservative treatment of ovarian torsion is encouraged with gradual 
detorsion of the organ.  
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Introduction. Chronic heart failure (CHF) is a severe health problem today, which is the most 
common cause of death globally. Half of the patients primarily diagnosed with heart failure, 
will die within 4 years, whereas those with severe heart failure will die within a year, in more 
than 50% of cases. This problem underpins the importance of an early diagnosis and risk 
stratification of the patients suffering from heart failure.  
Aim of the study. The aim of the study was to determine the role of the natriuretic peptide 
(NP) family in the pathogenesis of chronic heart failure, as well as the biomarker potential in 
early diagnosis of the disease.  
Materials and methods. A descriptive review was carried out, based on the scientific articles 
published during 2016-2020 in journals from PubMed and Google Scholar databases, by using 
the keywords "natriuretic peptide" and "chronic heart failure".  
Results. The NP system is represented by five structurally similar peptides: ANP – atrial 
natriuretic peptide, BNP – brain natriuretic peptide, CNP – C-type natriuretic peptide, and DNP 
– dendroaspis natriuretic peptide. NPs interfere with blood pressure regulation by decreasing 
systemic vascular resistance, increasing the cardiac output, regulating the hydroelectrolyte 
balance by promoting natriuresis and diuresis due to neuro-hormonal suppression (renin-
angiotensin-aldosterone system, norepinephrine, and endothelin-1) and exhibiting anti-
proliferative and anti-fibrotic effects. Thus, the NPS are counteracting the main 
pathophysiological mechanisms found in patients with HF.  The plasma NP levels can be used 
for initial diagnosis, especially in non-severe clinical presentation. Patients with normal NP 
levels are less likely to develop HF. B-type natriuretic peptide (BNP) and N-terminal 
propeptide of BNP (NT-proBNP) are the key members of the natriuretic peptide family, which 
have been recommended as gold standard biomarkers for heart failure diagnosis and prognosis 
(2016 ESC Guidelines on diagnosis and treatment of acute and chronic heart failure). 35 pg/ml 
for BNP and 125 pg/ml for NT-proBNP are the upper reference values in non-acute cases. The 
following factors should be considered when interpreting the BNP values: age (elderly people 
have higher BNP values), concomitant therapies and renal function. High NP values might be 
found in other cardiac and non-cardiac disease.  
Conclusions. In case of CHF, BNP and NT-proBNP assessment is the most significant marker 
in diagnosing and stratifying the severity of the disease at its onset, since high levels of NP 
leads to recurrent hospitalization and sudden cardiac arrest.  
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